

Mairad Mcnamara

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3483355/mairead-mcnamara-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

128
papers

4,344
citations

30
h-index

64
g-index

145
ext. papers

5,411
ext. citations

4.5
avg, IF

5.55
L-index

#	Paper	IF	Citations
128	Hepatopancreaticobiliary Cancer in Older Adults with Frailty 2022 , 421-445		
127	Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapy.. <i>Acta Oncologica</i> , 2022 , 1-8	3.2	0
126	Distal migration of a partially covered duodenal stent requiring emergency surgical extraction. <i>International Journal of Gastrointestinal Intervention</i> , 2022 , 11, 89-93	0.2	
125	Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021 , 101, 102299	14.4	
124	HPB cancers in older patients inclusion of older/senior patients in clinical trials. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 597-602	3.6	2
123	Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021 , 94, 102168	14.4	1
122	Chemotherapy for advanced gallbladder cancer (GBC): A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 163, 103328	7	7
121	Systemic therapies in advanced hepatocellular carcinoma: How do older patients fare?. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 583-590	3.6	6
120	Outcomes in older patients with biliary tract cancer. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 569-575	3.6	2
119	A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08). <i>Oncologist</i> , 2021 , 26, e669-e678	5.7	5
118	In Reply. <i>Oncologist</i> , 2021 , 26, e903-e904	5.7	
117	The Microbiome as a Potential Target for Therapeutic Manipulation in Pancreatic Cancer. <i>Cancers</i> , 2021 , 13,	6.6	2
116	Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis. <i>Cancer Treatment Reviews</i> , 2021 , 99, 102258	14.4	9
115	Heterocellular OSM-OSMR signalling reprograms fibroblasts to promote pancreatic cancer growth and metastasis.. <i>Nature Communications</i> , 2021 , 12, 7336	17.4	4
114	Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 200-210	9.7	53
113	The assessment of pancreatic exocrine function in patients with inoperable pancreatic cancer: In need of a new gold-standard. <i>Pancreatology</i> , 2020 , 20, 668-675	3.8	7
112	NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC). <i>BMJ Open</i> , 2020 , 10, e034527	3	6

111	Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920915299	5.4	8
110	NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials. <i>Medical Oncology</i> , 2020 , 37, 61	3.7	5
109	Assessing Full Benefit of Rivaroxaban Prophylaxis in High-Risk Ambulatory Patients with Cancer: Thromboembolic Events in the Randomized CASSINI Trial. <i>TH Open</i> , 2020 , 4, e107-e112	2.7	8
108	Molecular targeted therapies: Ready for "prime time" in biliary tract cancer. <i>Journal of Hepatology</i> , 2020 , 73, 170-185	13.4	107
107	Extrapulmonary poorly differentiated NECs, including molecular and immune aspects. <i>Endocrine-Related Cancer</i> , 2020 , 27, R219-R238	5.7	8
106	RELEVANT study: Patient (Pt) and physician (PI) perspectives on meaningful outcomes in advanced pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 150-150	2.2	
105	Clinical and Translational Research Challenges in Biliary Tract Cancers. <i>Current Medicinal Chemistry</i> , 2020 , 27, 4756-4777	4.3	10
104	NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121). <i>Future Oncology</i> , 2020 , 16, 1069-1081	3.6	12
103	Prognostic importance of lymph node yield after curative resection of gastroenteropancreatic neuroendocrine tumours. <i>World Journal of Clinical Oncology</i> , 2020 , 11, 205-216	2.5	3
102	Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. <i>Journal of Hepatology</i> , 2020 , 73, 1109-1117	13.4	9
101	Current standards and future perspectives in adjuvant treatment for biliary tract cancers. <i>Cancer Treatment Reviews</i> , 2020 , 84, 101936	14.4	34
100	Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study. <i>Cancer Medicine</i> , 2020 , 9, 6196-6204	4.8	7
99	Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs). <i>Cancers</i> , 2020 , 12,	6.6	4
98	Fibrolamellar carcinoma: Challenging the challenge. <i>European Journal of Cancer</i> , 2020 , 137, 144-147	7.5	2
97	Impact of high tumor mutational burden in solid tumors and challenges for biomarker application. <i>Cancer Treatment Reviews</i> , 2020 , 89, 102084	14.4	18
96	Impact on prognosis of early weight loss during palliative chemotherapy in patients diagnosed with advanced pancreatic cancer. <i>Pancreatology</i> , 2020 , 20, 1682-1688	3.8	5
95	Outcomes in patients [30] years with a diagnosis of a hepatopancreaticobiliary (HPB) malignancy. <i>Medical Oncology</i> , 2019 , 36, 85	3.7	4
94	Biliary tract cancers: current knowledge, clinical candidates and future challenges. <i>Cancer Management and Research</i> , 2019 , 11, 2623-2642	3.6	47

93	Adjuvant chemotherapy and outcomes in patients with nodal and resection margin-negative pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. <i>Journal of Surgical Oncology</i> , 2019 , 119, 932-940	2.8	8
92	A strategy for early detection of response to chemotherapy drugs based on treatment-related changes in the metabolome. <i>PLoS ONE</i> , 2019 , 14, e0213942	3.7	5
91	F-fluorodeoxyglucose positron emission tomography (FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2019 , 71, 115-129	13.4	35
90	Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer. <i>Scientific Reports</i> , 2019 , 9, 11610	4.9	18
89	Response to: Assessing the risk of bias and publication bias should be integral parts of the systematic review. <i>European Journal of Cancer</i> , 2019 , 118, 189	7.5	
88	Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes. <i>Cancer Management and Research</i> , 2019 , 11, 7537-7556	3.6	3
87	Follow-Up Recommendations after Curative Resection of Well-Differentiated Neuroendocrine Tumours: Review of Current Evidence and Clinical Practice. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	5
86	Response to letter to the editor: The impact of the nodal status and resection margin on the effectiveness of adjuvant chemotherapy for pancreatic cancer: It calls for more careful evaluation. <i>Journal of Surgical Oncology</i> , 2019 , 120, 1055	2.8	
85	Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres. <i>World Journal of Gastroenterology</i> , 2019 , 25, 5991-6005	5.6	26
84	Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC). <i>Clinical and Translational Oncology</i> , 2019 , 21, 950-953	3.6	2
83	The importance of quality-of-life management in patients with advanced pancreatic ductal adenocarcinoma. <i>Current Problems in Cancer</i> , 2018 , 42, 26-39	2.3	15
82	Biliary Tract Cancer: Implicated Immune-Mediated Pathways and Their Associated Potential Targets. <i>Oncology Research and Treatment</i> , 2018 , 41, 298-304	2.8	6
81	Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy. <i>Cancers</i> , 2018 , 10,	6.6	14
80	Irreversible Electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional treatment?. <i>European Journal of Surgical Oncology</i> , 2018 , 44, 1486-1493	3.6	7
79	Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018 , 12, 723-731	4.2	26
78	Selumetinib (Sel) and cisplatin/gemcitabine (CisGem) for advanced biliary tract cancer (BTC): A randomized trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4084-4084	2.2	1
77	PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours. <i>Oncotarget</i> , 2018 , 9, 14922-14938	3.3	21
76	Health-related quality of life, anxiety, depression and impulsivity in patients with advanced gastroenteropancreatic neuroendocrine tumours. <i>World Journal of Gastroenterology</i> , 2018 , 24, 671-679	5.6	9

75	Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis. <i>European Journal of Cancer</i> , 2018 , 105, 1-9	7.5	41
74	The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers. <i>PLoS ONE</i> , 2018 , 13, e0206007	3.7	10
73	Biliary Tract Cancer: State of the Art and potential role of DNA Damage Repair. <i>Cancer Treatment Reviews</i> , 2018 , 70, 168-177	14.4	41
72	Elderly patients diagnosed with hepatopancreatobiliary malignancies: A challenge beyond resection. <i>Cancer</i> , 2017 , 123, 888-890	6.4	2
71	Treatment Outcomes in 1p19q Co-deleted/Partially Deleted Gliomas. <i>Canadian Journal of Neurological Sciences</i> , 2017 , 44, 288-294	1	9
70	The dark side of T1 non-appendiceal small bowel neuroendocrine tumors. <i>Human Pathology</i> , 2017 , 66, 239-240	3.7	
69	Neutrophil-lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival. <i>Journal of Neuro-Oncology</i> , 2017 , 132, 463-471	4.8	52
68	HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?. <i>Cancer and Metastasis Reviews</i> , 2017 , 36, 141-157	9.6	79
67	Long term responders to palliative chemotherapy for advanced biliary tract cancer. <i>Journal of Gastrointestinal Oncology</i> , 2017 , 8, 352-360	2.8	8
66	Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	18
65	Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials. <i>BMC Cancer</i> , 2017 , 17, 262	4.8	12
64	Update on Treatment Options for Advanced Bile Duct Tumours: Radioembolisation for Advanced Cholangiocarcinoma. <i>Current Oncology Reports</i> , 2017 , 19, 50	6.3	12
63	Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib. <i>Clinical and Translational Oncology</i> , 2017 , 19, 364-372	3.6	10
62	Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	15
61	Germline mutations in pancreatic cancer and potential new therapeutic options. <i>Oncotarget</i> , 2017 , 8, 73240-73257	3.3	33
60	Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. <i>Annals of Oncology</i> , 2016 , 27, 134-40	10.3	69
59	Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems. <i>Future Oncology</i> , 2016 , 12, 2561-2578	3.6	3
58	Telotristat ethyl: a new option for the management of carcinoid syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 2487-2498	4	22

57	Predictive and prognostic values of ERCC1 and XRCC1 in biliary tract cancers. <i>Journal of Clinical Pathology</i> , 2016 , 69, 695-701	3.9	8
56	"If You Prick Us, Do We Not Bleed?" Whom Should We Choose?. <i>Journal of Clinical Oncology</i> , 2016 , 34, 513-4	2.2	3
55	Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?. <i>Cancer Treatment Reviews</i> , 2016 , 44, 26-41	14.4	34
54	¹⁸ F-FLT PET imaging of cellular proliferation in pancreatic cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 99, 158-69	7	8
53	Impact of biliary stent-related events in patients diagnosed with advanced pancreatobiliary tumours receiving palliative chemotherapy. <i>World Journal of Gastroenterology</i> , 2016 , 22, 6065-75	5.6	15
52	Pancreatic cancer: Are "liquid biopsies" ready for prime-time?. <i>World Journal of Gastroenterology</i> , 2016 , 22, 7175-85	5.6	20
51	Detection of Early Tumor Response to Axitinib in Advanced Hepatocellular Carcinoma by Dynamic Contrast Enhanced Ultrasound. <i>Ultrasound in Medicine and Biology</i> , 2016 , 42, 1303-11	3.5	12
50	Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery. <i>Surgical Oncology</i> , 2016 , 25, 223-8	2.5	11
49	Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer. <i>European Journal of Cancer</i> , 2015 , 51, 1381-8	7.5	16
48	Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide. <i>Journal of Neuro-Oncology</i> , 2015 , 124, 119-26	4.8	45
47	To BRCA or Not to PALB. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2581-2	2.2	1
46	Outcome of adjuvant therapy in biliary tract cancers. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015 , 38, 382-7	2.7	28
45	A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma. <i>Cancer</i> , 2015 , 121, 1620-7	6.4	37
44	Do recurrent and de novo metastatic biliary tract cancer patients have the same outcome on treatment?. <i>Journal of Clinical Oncology</i> , 2015 , 33, 351-351	2.2	1
43	Patterns of care and treatment outcomes in older patients with biliary tract cancer. <i>Oncotarget</i> , 2015 , 6, 44995-5004	3.3	18
42	Effect of body mass index on outcomes in biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 399-399	2.2	
41	Prognostic score in high-grade gastrointestinal neuroendocrine tumours (GI-NETs).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4089-4089	2.2	
40	Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era. <i>Journal of Neuro-Oncology</i> , 2014 , 117, 153-60	4.8	21

39	Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression. <i>Journal of Neuro-Oncology</i> , 2014 , 117, 147-52	4.8	62
38	Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 1204-12	4	401
37	Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer. <i>European Journal of Cancer</i> , 2014 , 50, 1581-9	7.5	94
36	Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. <i>Journal of the National Cancer Institute</i> , 2014 , 106, dju124	9.7	1552
35	RT-20 * DELAYING RADIOTHERAPY IN 1p19q CO-DELETED AND PARTIALLY DELETED GLIOMAS. <i>Neuro-Oncology</i> , 2014 , 16, v191-v191	1	78
34	Glioblastoma treatment in the elderly in the temozolomide therapy era. <i>Canadian Journal of Neurological Sciences</i> , 2014 , 41, 357-62	1	4
33	Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. <i>Cancer</i> , 2014 , 120, 3346-52	6.4	98
32	Use and misuse of waterfall plots. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	17
31	Systemic therapy for hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2014 , 1, 23-38	4	
30	RT-19 * PROGNOSTIC VALUE OF EARLY CHANGES IN NEUTROPHIL AND LYMPHOCYTE MEASURES DURING CHEMORADIOTHERAPY FOR GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2014 , 16, v191-v191	1	78
29	Effects of statin, aspirin, or metformin use on recurrence free and overall survival in patients with biliary tract cancer (BTC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 303-303	2.2	2
28	Patterns of care and treatment outcomes in older patients with biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 315-315	2.2	
27	Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study. <i>European Journal of Cancer</i> , 2013 , 49, 329-35	7.5	88
26	Anaplastic oligodendroglioma: advances and treatment options. <i>Current Treatment Options in Neurology</i> , 2013 , 15, 289-301	4.4	10
25	State-of-the-art in the management of locally advanced and metastatic gallbladder cancer. <i>Current Opinion in Oncology</i> , 2013 , 25, 425-31	4.2	21
24	Sequence dependence of MEK inhibitor AZD6244 combined with gemcitabine for the treatment of biliary cancer. <i>Clinical Cancer Research</i> , 2013 , 19, 118-27	12.9	20
23	Emerging biomarkers in anaplastic oligodendroglioma: implications for clinical investigation and patient management. <i>CNS Oncology</i> , 2013 , 2, 351-8	4	6
22	Emerging biomarkers in glioblastoma. <i>Cancers</i> , 2013 , 5, 1103-19	6.6	69

21	Neutrophil/lymphocyte ratio (NLR) as a prognostic factor in biliary tract cancer (BTC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4130-4130	2.2	1
20	A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 314-314	2.2	
19	Antiangiogenic therapies in glioblastoma multiforme. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 643-54	3.5	26
18	Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: A large retrospective study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e14524-e14524	2.2	
17	Outcome of adjuvant therapy for biliary tract cancers.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e14592-e14592		
16	Management of glioblastoma in the elderly. <i>Clinical Advances in Hematology and Oncology</i> , 2012 , 10, 379-86	0.6	11
15	Emergence of MRSA in positive blood cultures from patients with febrile neutropenia—a cause for concern. <i>Supportive Care in Cancer</i> , 2008 , 16, 1085-8	3.9	38
14	Lipids and essential fatty acids in patients presenting with self-harm. <i>British Journal of Psychiatry</i> , 2007 , 190, 112-7	5.4	60
13	3,4-methylenedioxymethamphetamine (MDMA; Ecstasy) administration produces dose-dependent neurochemical, endocrine and immune changes in the rat. <i>Human Psychopharmacology</i> , 1999 , 14, 95-104 ^{2.3}		15
12	Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression. <i>European Journal of Pharmacology</i> , 1999 , 364, 123-32	5.3	73
11	Royal academy of medicine in Ireland section of biomedical sciences. <i>Irish Journal of Medical Science</i> , 1998 , 167, 51-63	1.9	
10	Acute 3,4-methylenedioxymethamphetamine(MDMA) administration produces a rapid and sustained suppression of immune function in the rat. <i>Immunopharmacology</i> , 1998 , 38, 253-60		49
9	Chronic imipramine treatment upregulates IR2-imidazoline receptive sites in rat brain. <i>Neurochemistry International</i> , 1997 , 30, 101-7	4.4	12
8	BIMT 17: a putative antidepressant with a fast onset of action?. <i>Psychopharmacology</i> , 1997 , 134, 378-86	4.7	30
7	Royal academy of medicine in Ireland section of biomedical sciences. <i>Irish Journal of Medical Science</i> , 1996 , 165, 224-238	1.9	
6	Some behavioural and neurochemical effects of ipsapirone in two rodent models of depression. <i>Journal of Psychopharmacology</i> , 1996 , 10, 126-33	4.6	5
5	Swim stress increases the potency of glycine at the N-methyl-D-aspartate receptor complex. <i>Journal of Neurochemistry</i> , 1995 , 64, 925-7	6	34
4	Some behavioural and neurochemical aspects of subacute (+/-)3,4-methylenedioxymethamphetamine administration in rats. <i>Pharmacology Biochemistry and Behavior</i> , 1995 , 52, 479-84	3.9	62

3	Royal academy of medicine in ireland section of biomedical sciences. <i>Irish Journal of Medical Science</i> , 1995 , 164, 311-319	1.9	
2	The effect of acute MDMA administration on body temperature, serum corticosterone and neurotransmitter concentrations in male and female rats. <i>Human Psychopharmacology</i> , 1995 , 10, 373-383 ^{2,3}	14	
1	Royal academy of medicine in Ireland section of biomedical sciences. <i>Irish Journal of Medical Science</i> , 1994 , 163, 258-268	1.9	0